Literature DB >> 35049127

Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia.

Sylvie Belleville1,2, Simon Cloutier1,2, Samira Mellah1, Sherry Willis3, Bruno Vellas4,5,6, Sandrine Andrieu5,6,7, Nicola Coley5,6,7, Tiia Ngandu8.   

Abstract

BACKGROUND: Little is known regarding the dose-response function in multidomain interventions for dementia prevention.
METHOD: The Multidomain Alzheimer Preventive Trial is a 3-year randomized controlled trial comprising cognitive training, physical activity, nutrition, and omega-3 polyunsaturated fatty acids for at-risk older adults. The dose delivered (number of sessions attended) was modeled against global cognition, memory, and fluency in 749 participants. Interaction effects were assessed for age, sex, education, dementia score (CAIDE), frailty score, and apolipoprotein E (APOE) ε4 status.
RESULTS: The dose-response models were non-linear functions indicating benefits up to about 12 to 14 training hours or 15 to 20 multidomain sessions followed by a plateau. Participants who benefited from a higher dose included women, younger participants, frail individuals, and those with lower education or lower risk of dementia. DISCUSSION: The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. The optimal dose was about half of the potentially available sessions.
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  cognitive aging; cognitive decline; cognitive training; dementia; dosage; dose-response; intervention; multidomain; prevention

Year:  2022        PMID: 35049127     DOI: 10.1002/alz.12544

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  4 in total

1.  Multidomain trials to prevent dementia: addressing methodological challenges.

Authors:  Manuel Montero-Odasso; G Y Zou; Nellie Kamkar; Howard H Feldman; Sylvie Belleville; Howard Chertkow; Haakon B Nygaard; Surim Son; Mark Speechley
Journal:  Alzheimers Res Ther       Date:  2022-07-11       Impact factor: 8.823

2.  Upping the dose of dementia risk reduction.

Authors:  Timothy Daly
Journal:  Alzheimers Dement       Date:  2022-05-08       Impact factor: 16.655

3.  Parallel randomized controlled feasibility trials of the "Active Brains" digital intervention to protect cognitive health in adults aged 60-85.

Authors:  Rosie Essery; Sebastien Pollet; Katherine Bradbury; Max J Western; Elisabeth Grey; James Denison-Day; Kirsten A Smith; Victoria Hayter; Joanne Kelly; Jane Somerville; Beth Stuart; Taeko Becque; Jin Zhang; Joanna Slodkowska-Barabasz; Fiona Mowbray; Anne Ferrey; Guiqing Yao; Shihua Zhu; Tony Kendrick; Simon Griffin; Nanette Mutrie; Sian Robinson; Helen Brooker; Gareth Griffiths; Louise Robinson; Martin Rossor; Clive Ballard; John Gallacher; Shanaya Rathod; Bernard Gudgin; Rosemary Phillips; Tom Stokes; John Niven; Paul Little; Lucy Yardley
Journal:  Front Public Health       Date:  2022-09-20

4.  Response to "Upping the dose of dementia risk reduction".

Authors:  Sylvie Belleville; Simon Cloutier; Samira Mellah; Bruno Vellas; Sandrine Andrieu; Nicola Coley; Tiia Ngandu
Journal:  Alzheimers Dement       Date:  2022-05-16       Impact factor: 16.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.